Lexaria inks licensing deal for drug delivery tech with Premier Wellness for Japan market
seekingalpha.com
science
2022-06-03 08:37:36

mediaphotos/iStock via Getty Images Lexaria Bioscience (NASDAQ:LEXX) signed a licensing agreement with Japans' Premier Wellness Science for its drug delivery technology DehydraTECH. Under the agreement, Premier, a unit of Tokyo-listed Premier Anti-Aging, is buying rights to DehydraTECH technology for the Japanese non-pharmaceutical market for use with CBD and hemp ingredients in oral liquid and non-liquid products, and for topical, hair-care, lip-care and cosmetics products. Lexaria said that to retain ongoing exclusivity, the minimum quarterly payments to it begin Sept.
